SethKarolMDMSCI(He/Him)
Pediatric Hematology & Oncology • Memphis, TNAssociate Member- Leukemia/ Lymphoma Division St. Jude Children's Research Hospital
Dr. Karol is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 38105
Summary
- Dr. Seth Karol is a pediatric hematologist/oncologist in Memphis, TN and is affiliated with St. Jude Children's Research Hospital. He received his medical degree from The Ohio State University College of Medicine and has been in practice as a pediatric oncologist since 2012. He has expertise in experienced acute lymphoblastic leukemia, acute myeloid leukemia, treatment side effects, early phase clinical trials, and pharmacogenomics.
Education & Training
University of TennesseeFellowship, Pediatric Hematology/Oncology, 2012 - 2015
Case Western Reserve Univ/Univ Hosps Cleveland Med Ctr/Rainbow Babies and Childrens HospitalResidency, Pediatrics, 2008 - 2011
Ohio State University College of MedicineClass of 2008
Certifications & Licensure
TN State Medical License 2012 - 2025
OH State Medical License 2008 - 2012
American Board of Pediatrics Pediatrics- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase Start of enrollment: 2020 Sep 04
- Hypertension Intervention to Reduce Osteonecrosis in Children With Acute Lymphoblastic Leukemia/Lymphoma Start of enrollment: 2020 Oct 15
- Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) Start of enrollment: 2022 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- The Use of Fresh Osteoarticular Allografts for Steroid-induced Osteonecrosis of the Femoral Condyle With Collapse in Childhood Cancer Patients: Single-institutional Ex...Michael D Neel, Sandra W Murphy, Sue C Kaste, Brian M Defeo, Seth E Karol
Journal of Pediatric Orthopedics. 2025-04-01 - Clinical Actionability of the NUDT15 *4 (p.R139H) Allele and Its Association With Hispanic Ethnicity.Maud Maillard, Jenny Q Nguyen, Wenjian Yang, Keito Hoshitsuki, Mary V Relling
Clinical Pharmacology and Therapeutics. 2025-03-01 - Changes in asparaginase exposure and toxicity profiles in obese pediatric acute lymphoblastic leukemia patients.John C Panetta, Emily Ashcraft, Sima Jeha, Ching-Hon Pui, Hiroto Inaba
Haematologica. 2025-02-13
Lectures
- Safety and activity of venetoclax in combination with high-dose cytarabine in children with relapsed or refractory acute myeloid leukemia.ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
- Safety, Efficacy, and PK of the BCL2 Inhibitor Venetoclax in Combination with Chemotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Press Mentions
Venetoclax plus High-Dose Cytarabine with or Without Idarubicin Well Tolerated in Pediatric AMLMay 1st, 2020
ASH Annual Meeting Highlights St. Jude ResearchDecember 6th, 2019
Venetoclax Combo Therapy Shows Promise in Pediatric Patients with R/R AMLJune 14th, 2019- Join now to see all
External Links
- St. Jude profilehttp://www.stjude.org/karol
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
